![Wolfgang Oster](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Wolfgang Oster
Directeur/Membre du Conseil chez
IMI Intelligent Medical Implants AG
Profil
Wolfgang Oster is the founder of Oncoceutics, Inc. which was founded in 2009.
He held the title of Chairman & Chief Executive Officer at Oncoceutics, Inc. Dr. Oster's current job(s) include being a Director at IMI Intelligent Medical Implants AG since 2009 and holding the title of Principal at the University of Freiburg.
Dr. Oster's former job(s) include being Vice Chairman at Cappella, Inc. from 2010 to 2011, being a Member-Management Board at AplaGen GmbH, and being a Managing Partner at PolyTechnos Venture-Partners GmbH.
Postes actifs de Wolfgang Oster
| Sociétés | Poste | Début |
|---|---|---|
IMI Intelligent Medical Implants AG
 IMI Intelligent Medical Implants AG Medical DistributorsDistribution Services Develops retinal implant system | Directeur/Membre du Conseil | 27/04/2010 |
University of Freiburg
 University of Freiburg Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Anciens postes connus de Wolfgang Oster
| Sociétés | Poste | Fin |
|---|---|---|
AplaGen GmbH
 AplaGen GmbH BiotechnologyHealth Technology Develops and markets therapeutic peptides | Corporate Officer/Principal | 01/06/2009 |
Oncoceutics, Inc.
 Oncoceutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops imipridones for cancer treatment | Directeur Général | - |
PolyTechnos Venture-Partners GmbH
 PolyTechnos Venture-Partners GmbH Investment ManagersFinance PTVP originally focused on early-stage investing in advanced technology sectors, then evolved towards later-stage investments. Their portfolio companies are typically European high-growth companies where they identified a special situation likely to create significant value within a short period of time, a unique business model, limited technology risk, limited burn rate, and an identified value inflection point for a global trade sale or an IPO. PTVP's focus is on German-speaking countries. They provide hands-on support to promote the global development of their investee companies. Their portfolio is invested in sectors including software, information technology, life sciences, energy and clean technology, as well as in companies born of the convergence of these fields. | Private Equity Investor | - |
Cappella, Inc.
 Cappella, Inc. Pharmaceuticals: MajorHealth Technology Operates as a medical device company | Président | 05/08/2010 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
14
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Cappella, Inc.
Cappella, Inc. Pharmaceuticals: MajorHealth Technology Operates as a medical device company | Health Technology |
University of Freiburg
University of Freiburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IMI Intelligent Medical Implants AG
IMI Intelligent Medical Implants AG Medical DistributorsDistribution Services Develops retinal implant system | Distribution Services |
AplaGen GmbH
AplaGen GmbH BiotechnologyHealth Technology Develops and markets therapeutic peptides | Health Technology |
PolyTechnos Venture-Partners GmbH
PolyTechnos Venture-Partners GmbH Investment ManagersFinance PTVP originally focused on early-stage investing in advanced technology sectors, then evolved towards later-stage investments. Their portfolio companies are typically European high-growth companies where they identified a special situation likely to create significant value within a short period of time, a unique business model, limited technology risk, limited burn rate, and an identified value inflection point for a global trade sale or an IPO. PTVP's focus is on German-speaking countries. They provide hands-on support to promote the global development of their investee companies. Their portfolio is invested in sectors including software, information technology, life sciences, energy and clean technology, as well as in companies born of the convergence of these fields. | Finance |
Oncoceutics, Inc.
Oncoceutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops imipridones for cancer treatment | Health Technology |
